Prestige Consumer Healthcare Inc.

Key metrics

Financial performance

Over the last 9 fiscal years Prestige Consumer Healthcare Inc.'s revenue grew from $882.06M to $1.09B, a compound annual growth rate of 2.4%. Net profit margin expanded from 7.9% to 17.5% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,235 filings)

Recent press releases

• Boston" Rob Mariano and Dramamine® Team Up to Champion Summer Travel Driven by Your2026-05-18

  TARRYTOWN, N.Y. , May 18, 2026 /PRNewswire/ -- The most meaningful trips aren't defined by the destination, but by the purpose behind them. Dramamine ® , the #1 brand for nausea relief, is encouraging travelers to tune in to the 'why' behind their journeys with the debut of the ' Your Why. Your Way. ' campaign. Whether seeking adventure or challenging themselves to go somewhere new, Dramamine ® invites people to embrace traveling with purpose knowing that its selection of nausea solutions won't let nausea stand in the way of the experiences that matter most.

• Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health2026-05-13

  Reported revenues of $281.6 million in Q4 and $1,088.7 million in fiscal year 2026

• Prestige Consumer Healthcare to Release Fiscal 2026 Fourth Quarter and Year-End Earnings Results2026-04-30

  To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com . To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.

• Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips2026-03-20

  Entered agreement to acquire a portfolio of brands with revenue of $200 million and EBITDA of $95 million

• Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results2026-02-05

  Diluted EPS of $0.97 in Q3 and Adjusted Diluted EPS of $1.14 , versus prior year Q3 Diluted EPS of $1.22

Similar companies

The largest companies sharing Prestige Consumer Healthcare Inc.'s SEC industry classification (pharmaceutical preparations).